Development and evaluation of PreS1-targeted HBV mRNA vaccine
NARH PHILIP Amor
LIN Ang
Abstract：Objective To design and develop a therapeutic mRNA vaccine encoding HBV PreS1 antigen with strong immunogenicity.Methods Based on the PreS1 antigen sequence of GenotypeC-Adr subtype HBV strains that commonly infect Chinese patients,mRNA vaccine sequences was designed and optimized using different platforms with the addition of T7 RNA polymerase promoter,UTR sequence,and signal peptide.The mRNA was then efficiently encapsulated with an ion-izable lipid-based LNP,and mice were immunized via intramuscular injection.Subsequently,antibody levels in serum were detected using ELISA,and antigen-specific responses of splenic T cells were validated by ELISpot to assess the immunoge-nicity of the mRNA vaccine.ResuIts Compared to the control group,mice in the mRNA vaccine groups showed significantly increased levels of PreS1-specific IgG antibodies in serum(P<0.05).The ELISpot assay demonstrated that splenic T cells from the mRNA vaccine groups produced IFNγ in response to stimulation with PreS1 peptide pools.ConcIu-sion The therapeutic HBV mRNA vaccine encoding PreS1 antigen exhibited robust immunogenicity,inducing specific B cell(humoral immunity)and T cell responses(cellular immunity)in mice.
Keywords：Hepatitis B virusTherapeutic mRNA vaccineLipid nanoparticlesImmunogenicity
Publication Date：2024-11-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 1041-1044,1108 )